



**FRESENIUS  
KABI**

caring for life

# Biosimilars by Fresenius Kabi

Living beyond disease\*




\*Fresenius Kabi biosimilars include compounds at different stages of development

# Who is Fresenius Kabi?

Fresenius Kabi is a global healthcare company specializing in life-changing medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used for the therapy and care of critically and chronically ill patients. Our product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs.<sup>1</sup>

Fresenius Kabi is part of the Fresenius Group, which includes three other business segments, each one active in a vital area of healthcare. For over 100 years, a clear focus on innovation and efficiency has generated high-calibre products and services, helping to save and improve patients' lives across multiple therapy areas.<sup>2,3</sup>

## Fresenius Kabi<sup>1</sup>




# “Caring for life” is our mission

Putting patients first constitutes a fundamental part of our reputation, which we carry into our biosimilars portfolio. We harness our passion and commitment to put essential medicines and technologies in the hands of people who help patients, as well as helping to find the best answers to the challenges they face.

## Leveraging our global expertise and history to deliver solutions for patients

With significant experience in supplying healthcare partners with critical and chronic care products worldwide, we are well-equipped to consistently meet high-volume demands in urgent healthcare settings and committed to being dependable suppliers.<sup>3</sup>


### Our global footprint\*



100  
COUNTRIES



40,000+  
EMPLOYEES




# Fresenius Kabi is unlocking access to life-changing treatments through biosimilars

The growing availability of biosimilars provides patients with more treatment options and increased access to life-changing medicines, as well as reduced treatment costs for both patients and healthcare providers.<sup>5,6</sup> This is vitally important in the journey towards bettering patients' health and easing pressures on health systems, which are being tasked to do more with less.

In 2022, over **850 million** patient treatment days using biosimilars were recorded in Europe - a 13% increase from 750 million in 2021.<sup>7</sup> To date, biosimilars have led to **~4.5 billion** treatment days for European patients.<sup>7</sup>

Biosimilars from Fresenius Kabi offer healthcare professionals a high-quality and cost-effective alternative to reference products, for more patients worldwide.

## Projected global savings from biosimilars 2021-2026<sup>8</sup>




Biosimilars are expected to create significant global savings in medication expenditure, which can be utilised by health services to enhance the provision of patient care.

The projected savings for healthcare systems and patients between now and 2026 are forecasted to total approximately **€200 bn**.<sup>8</sup>

Savings converted from USD. Conversion rates accurate at time of preparation.

## Savings from the impact of biosimilar competition at list prices<sup>6</sup>



The predicted future cost savings generated through biosimilars can be substantiated by evidence of past savings.<sup>7</sup>

Over the last decade biosimilars have continued to deliver huge value to European healthcare systems, generating record-high list price savings compared to the pre-biosimilar costs of the reference product, year-on-year.<sup>7</sup>

In Europe to date, biosimilars have generated over **€30 bn** in cumulative savings at list prices.<sup>7</sup>

TD = treatment days.  
 Caveats: This figure is not equivalent to all savings and is therefore an under-estimate. The data does not include the impact of rebates or discounts, which may have been present prior to the introduction of biosimilars in small quantities, and are highly significant post-biosimilar entry as it is based on publicly available prices. Source: IQVIA MIDAS™ data from 2006 - 2022, using Euros as constant exchange rates; value includes all originator products with approved biosimilars from 2006 - 2022, covering the full European Economic Area (33 CTYs), calculated volume is in treatment days determined by WHO-DDD and where values are unavailable via Oncology Dynamics Physician Survey (2017) DDD estimates. Volume is solely biosimilar treatment days. Source: IQVIA MIDAS June 2022 MAT.

# Building upon years of pharmaceutical experience and technical knowledge with a growing biosimilars portfolio


Providing affordable and excellent healthcare to patients coping with chronic diseases and critical illness is an intrinsic part of Fresenius Kabi's purpose. This is demonstrated by our long-term commitment towards developing a comprehensive portfolio of biosimilars in oncology and immunology. Our dedication to biosimilars research and development (R&D) led to creating a state-of-the-art **R&D centre** in Switzerland with numerous biosimilar experts, so that more patients can receive the treatment they need and deserve.<sup>9</sup>

Our extensive portfolio of intravenous and injectable medicines, as well as years of pharmaceutical development experience, means that we are ideally positioned to deliver the benefits of biosimilars to you and your patients.

## Delivering for vital healthcare needs with biosimilars

Our biosimilars meet the high standards required by regulatory approval bodies based on totality of evidence across analytical, pharmacokinetic/pharmacodynamic, immunogenicity and clinical safety and efficacy assessments against the reference product.<sup>10</sup> They are produced in an established European facility with over 20 years' experience in manufacturing biologics.<sup>11</sup>

### Our biosimilars pipeline<sup>12</sup>



# KabiCare<sup>+</sup> from Fresenius Kabi

## Providing a holistic approach to patient care

We understand that living with a long-term health condition can be challenging, and that is why Fresenius Kabi is striving to help patients go beyond the disease with **KabiCare** - an educational and support program for patients who are being treated with our biosimilars, and healthcare professionals (HCPs).

KabiCare takes a holistic approach to a variety of patient needs and offers information, guidance and tools to support treatment onboarding and wellbeing. Patients can access clear, tailored and evidence-based content about their condition and treatment, as well as support with stress, keeping active, travelling, managing nutritional requirements and navigating relationships.<sup>16</sup>



**Information** on their condition



**Education** on biologics and biosimilars



**Training** taking their medicine



**Nutritional advice** tailored to their condition




**Starter kit** with instructions



**Comprehensive coaching tool**



**Tips and tricks** to support quality of life improvement



KabiCare is also an integrated support platform for HCPs and offers a suite of resources to help them inform and educate patients who are being treated with our biosimilars. This allows HCPs to actively engage patients in the decision making around their care and treatment. HCPs can also access the same content as their patients, as well as in-depth information about our biosimilar products including clinical study data, helpful downloads and online ordering of product demonstrations.

**So, whether a patient is initiating treatment on a biosimilar or switching to one, KabiCare is there to support them as they better manage the impact of their disease on day-to-day life.<sup>16</sup>**



**You can access KabiCare's on-line resources using [kabicare.nl](https://kabicare.nl) or reach out to your local Fresenius Kabi representative.**

# Working towards building a sustainable future

Our primary focus is meeting the needs of patients and HCPs through sustainable operation and management - an integral part of Fresenius Kabi's culture.

## A commitment to a better tomorrow

---

We have implemented mandatory environmental guidelines worldwide which provide a framework to actualize environmental protection, such as addressing and preventing environmental risks and preventing environmental incidents.

Our environmental management system primarily focuses on reducing energy and water use, as well as decreasing wastewater, waste, and emissions.

The energy management system is focused on improving energy performance and preventing excessive energy use. Our energy is mainly derived from external providers which includes renewable energy such as hydropower, solar, and wind power. We also generate electricity in our own facilities.

**We are working to introduce our environmental and energy management systems to all of our manufacturing plants worldwide by 2026.<sup>17</sup>**



Over the course of the last 19 years, we have **planted over 14,000 trees**, changing the landscape of our communities<sup>18</sup>



In 2019, we established a **Water and Energy Management Global Competence Cluster** - an internal information platform to exchange information on energy and water management practices<sup>17</sup>



**Biosimilars**



**100% of the electricity** at the sites where our biosimilars are produced is from **renewable sources**<sup>19</sup>



Almost all of the Fresenius Kabi and CMO sites in which our biosimilars are manufactured in are **ISO 14001** (environmental management) and **ISO 5001** (energy management) certified<sup>17</sup>



## References

1. Fresenius Kabi. Company. About us. Accessed from: <https://www.fresenius-kabi.com/company>. Last accessed: Dec 2022.
2. Fresenius Group: Fresenius. Group Overview. Accessed from: <https://www.fresenius.com/group-overview>. Last accessed: Dec 2022.
3. Biospecialized. About Fresenius Kabi. Accessed from: <https://biospecialized.com/about-fresenius-kabi/>. Last accessed Dec 2022.
4. European Medicines Agency (EMA). Biosimilars in the EU: Information guide for healthcare professionals. 2017. Accessed from: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Leaflet/2017/05/WC500226648.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf) Last accessed: Dec 2022.
5. Golshani S, Ali Faramarzi M. Expected Impact of Biosimilars on the Pharmaceutical Companies. *Iran J Med Sci*. 2021 Sep;46(5):399-401. doi: 10.30476/IJMS.2021.92314.2356.
6. Kim H, Alten H, Avendano L. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. *Drugs*. 2020. 80:99-113. <https://doi.org/10.1007/s40265-020-01256-5>.
7. Iqvia. Whitepaper. The Impact of Biosimilar Competition in Europe. 2022.
8. Iqvia Institute. The Global Use of Medicines 2022. Accessed From: <https://www.iqvia.com/-/media/iqvia/pdfs/library/publications/the-global-use-of-medicines-2022.pdf>. Last accessed Dec 2022.
9. Fresenius Kabi. Biosimilars. Accessed from <https://www.fresenius-kabi.com/therapeutic-areas/biosimilars>. Last accessed Dec: 2022
10. Biospecialized. Biosimilar Development. Accessed from: <https://www.fresenius-kabi.com/news/inauguration-biosimilars-r-d-center> Last accessed: Dec 2022
11. Biospecialized. Immunology. Accessed from: <https://biospecialized.com/our-experience/immunology-experience/>. Last accessed Dec: 2022
12. Fresenius Kabi. Products. Accessed from: <https://biosimilars.fresenius-kabi.com/products>. Last accessed: Dec 2022.
13. Fresenius Kabi. Idacio press release. 2022. Accessed from: <https://www.fresenius-kabi.com/news/fresenius-kabi-receives-fda-approval-for-biosimilar-Idacio>. Last accessed Jan 2023
14. Fresenius Kabi. Tocilizumab press release. Accessed from: <https://www.fresenius-kabi.com/news/biosimilar-candidate-tocilizumab-accepted-for-review-by-fda>. Last accessed: Dec 2022.
15. Fresenius Kabi. Stimufend press release. Accessed from <https://www.fresenius-kabi.com/news/fresenius-kabi-receives-us-fda-approval-for-biosimilar>. Last accessed: Dec 2022.
16. Fresenius Kabi. Kabi Care. Accessed from: <https://biosimilars.fresenius-kabi.com/kabicare#:~:text=KabiCare%20is%20an%20online%20education,are%20living%20with%20chronic%20conditions>. Last accessed: Dec 2022
17. Fresenius Kabi. Environment. Accessed from: <https://www.fresenius-kabi.com/responsibilities/environment#:~:text=Our%20Commitment%20to%20Tomorrow%3A%20Further,the%20well%2Dbeing%20of%20patients>. Last accessed: Dec 2022.
18. Fresenius Kabi. WeAreFreseniusKabi. Accessed from <https://www.fresenius-kabi.com/company/we-are-fresenius-kabi-with-a-true-purpose>. Last Accessed: Dec 2022.
19. Data on file







**FRESENIUS  
KABI**  
caring for life

Fresenius Kabi Nederland B.V.  
Postbus 565  
3700 AN Zeist, Nederland  
Tel.: 0800 - 022 19 05  
info.nl@fresenius-kabi.com  
www.fresenius-kabi.nl



2023-08-30/18 | August 2023